This new review article highlights the critical role of ribosome biogenesis in liver health and disease progression. As the center of protein synthesis, ribosomes influence liver regeneration, hepatitis C virus (HCV) infection, nonalcoholic fatty liver disease (NAFLD), liver fibrosis, cirrhosis, and hepatocellular carcinoma. The article explores how disruptions in this process contribute to disease and how targeted therapies could offer new treatment avenues.

This article explores a new therapeutic approach for rheumatoid arthritis (RA) using a combination of triptolide and medicarpin. Recent research published in Engineering reveals that targeting the m⁶A methylation pathway can significantly reduce bone destruction associated with RA. The study demonstrates that the combined use of triptolide and medicarpin effectively inhibits osteoclastogenesis and modulates inflammation, offering a potential strategy to improve treatment outcomes and minimize side effects in RA patients.

Gary Ulaner, MD, PhD, who serves as James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy at the Hoag Family Cancer Institute and is Professor of Radiology and Cancer Biology at the University of Southern California, has been elected vice president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2025 Annual Meeting, held June 21-24 in New Orleans.

Heather Jacene, MD, assistant chief of Nuclear Medicine and Molecular Imaging at Brigham and Women’s Hospital, clinical director of Nuclear Medicine at Dana-Farber Cancer Institute, and associate professor of Radiology at Harvard Medical School in Boston, Massachusetts, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2025 Annual Meeting, held June 21-24 in New Orleans.

Jean-Luc C. Urbain, MD, PhD, FASNC, professor of Radiology/Nuclear Medicine and Medicine, has been named president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2025 Annual Meeting, held June 21-24 in New Orleans.

A dual-protective approach using botulinum toxin (Botox) alongside an anti-nausea patch significantly reduces salivary gland toxicity in patients with metastatic prostate cancer undergoing PSMA-targeted radiopharmaceutical therapy. The strategy led to a 30 percent decrease in PSMA uptake by the salivary glands without affecting the treatment’s cancer-fighting efficacy. This reduction may enhance treatment adherence and improve overall patient outcomes. The findings were presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting.